Cosmos Health (NASDAQ: COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, has begun the application process to dual list its shares on Upstream. A trading app for digital securities and NFTs, Upstream is powered by Horizon Fintex and MERJ Exchange Limited. According to the announcement, Cosmos anticipates that the dual listing will provide the company with access to a global, digital-first investor base, enabling investors to trade with USDC digital currency as well as credit, debit, PayPal and USD; the move should increase the company’s liquidity, enhance price discovery and globalize the opportunity for investment. Approval for Upstream listing is subject to acceptance by MERJ; however, as an existing NASDAQ issuer, Cosmos Health may qualify for an expedited listing process. “Our application process to Upstream is yet another avenue we are exploring, in order to increase the liquidity of our stock by attracting international investors, and ultimately increasing shareholder value,” said Cosmos Health CEO Greg Siokas in the press release. “Given the global and innovative nature of our brands and products, it is important that we reach out to a global audience of investors who are not bound by geography or currency parameters, and Upstream is an important medium in that endeavor.”
To view the full press release, visit https://ibn.fm/M8l7L
About Cosmos Health Inc.
Cosmos Health is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products: Sky Premium Life and Mediterranation. Additionally, the company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and United Kingdom serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. For more information about this company, visit www.CosmosHoldings.com and www.SkyPremiumLife.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.